Table 4. Multivariable analysis for PFS... | American Society of Hematology

Table 4.

Multivariable analysis for PFS in the modern era

Variable	N (%)	Hazard ratio (95% CI)	P value
Age <45 y	146 (80%)	Reference	—
Age ≥45 y	37 (20%)	1.96 (1.01-3.84)	.049
Relapsed	133 (73%)	Reference	—
Refractory	50 (27%)	2.58 (1.44-4.63)	.0014
Metabolic CR	111 (61%)	Reference	—
Not in CR	72 (39%)	1.93 (1.06-3.50)	.031
Chemotherapy pre-AHCT∗	156 (85%)	Reference	—
PD-1 inhibitor pre-AHCT†	27 (15%)	0.21 (0.05-0.86)	.030

Variable	N (%)	Hazard ratio (95% CI)	P value
Age <45 y	146 (80%)	Reference	—
Age ≥45 y	37 (20%)	1.96 (1.01-3.84)	.049
Relapsed	133 (73%)	Reference	—
Refractory	50 (27%)	2.58 (1.44-4.63)	.0014
Metabolic CR	111 (61%)	Reference	—
Not in CR	72 (39%)	1.93 (1.06-3.50)	.031
Chemotherapy pre-AHCT∗	156 (85%)	Reference	—
PD-1 inhibitor pre-AHCT†	27 (15%)	0.21 (0.05-0.86)	.030

Bold values denote statistical significance at the P < .05 level.

N, number of patients.

Chemotherapy includes BV-based regimens but excludes regimens incorporating a PD-1 inhibitor.

Includes patients receiving a PD-1 inhibitor-based regimen as the last salvage therapy before AHCT.